Preclinical POC / Pharmacological models

Our proprietary efficacy models resulting from our Research and Development activity are a strategic decision-making support for clinical trials and help bolster regulatory application for IND.

Our translational non-human primate models are well suited for Proof of Concept (POC) studies in several therapeutic areas critical for Human health.

To achieve high quality efficacy studies, we combine outstanding scientific  knowledge, an in-depth expertise of the model, state-of-the-art technics, relevant clinical endpoints, robust study design, with a GLP-like data analysis, SOP and reporting.

 

The study parameters are customized to each project and goal, from the sampling method to the types of in vivo and ex vivo investigations.

To address particular issues relevant to drugs MOA, we can refine the characterization of our models based on the sponsor’s need, or even combine several models.

Infectious diseases

  • Bacterial infections
  • Human viral infections
  • Parasitic infections
  • Viral/bacterial co-infection

 

Respiratory diseases

  • Viral respiratory infections
  • Respiratory bacterial infections
  • Lung inflammation

 

Immune disorders & Inflammation

  • Multiple sclerosis
  • Psoriasis
  • Skin graft survival

CNS diseases

  • Multiple sclerosis
  • Ischemic stroke

 

 

 

Cardiometabolic diseases

  • Post-ischemic heart failure
  • Diet-induced atherosclerosis

 

Bone & musculoskeletal diseases

  • Post-traumatic Osteoarthritis model
  • Cartilage defect

The study parameters are adapted to each project and goal, from the ROA, sampling method to the types of in vivo and ex vivo investigations and bioanalysis.

To address particular issues relevant to patients, we can refine the characterization of our models based on the sponsor’s need, or combine several models.

Share this!